Organogenesis Holdings Inc. (ORGO) Report Analysis
Corporate Events
Organogenesis Holdings Inc. Approves Amendments to Certificate of Incorporation
2022-06-27 20:19:00
Organogenesis Holdings Inc. approved an amendment to Certificate of Incorporation, which amends Article V, Section 5.3 of Certificate of Incorporation to remove a provision that states that a director may be removed by stockholders only for cause, at the AGM held on June 23, 2022.
Organogenesis Holdings Inc. - Shareholder/Analyst Call
2022-05-10 20:18:00
Annual General Meeting
Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022
2022-05-10 20:05:00
Organogenesis Holdings Inc. provided earnings guidance for the year ending December 31, 2022. For the year, the company expected net revenue of between $485 million and $515 million, representing an increase of approximately 4% to 10% year-over-year as compared to net revenue of $468.1 million for the year ended December 31, 2021.
Organogenesis Holdings Inc. Announces Board Changes
2022-05-05 20:05:00
Organogenesis Holdings Inc. announced the appointments of Michele Korfin and Gilberto Quintero, Ph.D. to the Company’s Board of Directors, effective May 3, 2022. Ms. Korfin and Dr. Quintero will serve as independent directors of the Company. With the appointment of Ms. Korfin and Dr. Quintero, the Company’s board of directors has a majority of independent directors. Michele Korfin joined Gamida Cell’s leadership team as Chief Operating and Chief Commercial Officer in 2020. Prior to Gamida Cell, Michele served as Chief Operating Officer at TYME Technologies. Gilberto Quintero, Ph.D. has served as Chief Quality Officer of Global Quality, Regulatory and Compliance at Kimberly-Clark since 2019. Before joining Kimberly-Clark, Gilberto spent more than a decade at Cardinal Health in roles of increasing responsibility most recently serving as Chief Quality and Regulatory Affairs Officer for Pharmaceuticals and Medical Devices.
patientNOW, Inc, Rx Marketing Group, 17th Edition of the Music City Symposium for Cosmetic Advances & Laser Education, May 11, 2022 through May 15, 2022
2022-05-05 12:30:00
patientNOW, Inc, Rx Marketing Group, 17th Edition of the Music City Symposium for Cosmetic Advances & Laser Education, May 11, 2022 through May 15, 2022. Venue: Nashville, Tennessee, United States.
Organogenesis Holdings Inc., Annual General Meeting, Jun 23, 2022
2022-04-15 21:24:00
Organogenesis Holdings Inc., Annual General Meeting, Jun 23, 2022, at 11:00 US Eastern Standard Time. Agenda: To re-elect the directors;to approve, on an advisory basis, the compensation paid to named executive officers, as disclosed in this proxy statement; to approve, on an advisory basis, the frequency of holding an advisory vote on the compensation paid to named executive officers;to approve an amendment to certificate of incorporation (“Charter”) to remove a provision that states that directors may only be removed for cause; to approve an amendment to 2018 Equity Incentive Plan to increase the number of shares of Class A common stock reserved for issuance thereunder by 7,826,970 shares; to ratify the appointment of RSM US LLP as independent registered public accounting firm for fiscal year 2022; and to consider any other business properly presented at the meeting.
Organogenesis Holdings Inc. to Report Q1, 2022 Results on May 10, 2022
2022-04-05 20:05:00
Organogenesis Holdings Inc. announced that they will report Q1, 2022 results After-Market on May 10, 2022
Organogenesis Holdings Inc., Q1 2022 Earnings Call, May 10, 2022
2022-04-05 20:05:00
Organogenesis Holdings Inc., Q1 2022 Earnings Call, May 10, 2022
Pomerantz LLP Files Class Action Lawsuit Against Organogenesis Holdings Inc
2021-12-11 03:06:00
Pomerantz LLP announced that a class action lawsuit has been filed against Organogenesis Holdings Inc. and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-06845, is on behalf of a class consisting of all persons and entities other than defendants that purchased or otherwise acquired Organogenesis securities between March 17, 2021 and October 11, 2021, both dates inclusive (the class period), seeking to recover damages caused by defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the company and certain of its top officials. The complaint alleges that, throughout the class period, defendants made materially false and misleading statements regarding the company’s business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by, among other things, setting the price for those products multiple times higher than similar products; the company improperly induced doctors to use its Affinity and PuraPly XT products through lucrative reimbursements; as a result of all the foregoing, the company’s revenue and profits derived from its Affinity and PuraPly XT products were at least in substantial part unsustainable; and as a result, the company’s public statements were materially false and misleading at all relevant times.
Organogenesis Holdings Inc. - Shareholder/Analyst Call
2021-11-30 21:46:00
Annual Meeting of Stockholders
Organogenesis Holdings Inc., Annual General Meeting, Dec 29, 2021
2021-11-30 21:46:00
Organogenesis Holdings Inc., Annual General Meeting, Dec 29, 2021, at 11:00 US Eastern Standard Time. Agenda: To re-elect as the company's directors Alan A. Ades, Robert Ades, Prathyusha Duraibabu, David Erani, Jon Giacomin, Gary S. Gillheeney, Sr., Arthur S. Leibowitz and Glenn H. Nussdorf, each to serve until the next Annual Meeting of Stockholders and until their successors are elected and qualified; to ratify the appointment of RSM US LLP as the company's independent registered public accounting firm for fiscal year 2021; and to consider any other business properly presented at the meeting.
Organogenesis Holdings Inc. Appoints Prathyusha Duraibabu to Board of Directors
2021-11-22 12:00:00
Organogenesis Holdings Inc. announced the appointment of Prathyusha Duraibabu to the Company’s Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. Ms. Duraibabu currently serves as the Chief Financial Officer of Sangamo Therapeutics, a clinical stage biopharmaceutical company with a robust genomic medicines pipeline. Prior to joining Sangamo, Ms. Duraibabu was Corporate Controller at Pacific Biosciences of California Inc. from 2010 to 2019, a leading commercial DNA sequencing instrument company. Ms. Duraibabu began her career as an international tax and audit professional and served in a variety of accounting and finance roles of increasing responsibility for companies in the software and semiconductor sectors. She holds a Bachelors of Accounting from Oxford Brookes University, and an MBA from San Jose State University. She is a Certified Public Accountant.
Organogenesis Holdings Inc. Reports Write-Off of A Fixed Assets for the Third Quarter Ended September 30, 2021
2021-11-09 21:12:00
Organogenesis Holdings Inc. reported write-off of a fixed assets for the third quarter ended September 30, 2021. For the period, the company reported write-off of a fixed asset of $1,104,000.
Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2021
2021-11-09 21:05:00
Organogenesis Holdings Inc. provided earnings guidance for the year ending December 31, 2021. For the twelve months ending December 31, 2021, the Company now expects net revenue of between $458 million and $470 million, representing an increase of approximately 35% to 39% year-over-year, as compared to net revenue of $338.3 million for the twelve months ended December 31, 2020 and GAAP net income positive for the twelve months ended December 31, 2021.
SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022
2021-10-29 14:57:00
SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.
Organogenesis Holdings Inc., Q3 2021 Earnings Call, Nov 09, 2021
2021-10-07 20:05:00
Organogenesis Holdings Inc., Q3 2021 Earnings Call, Nov 09, 2021
Organogenesis Holdings Inc. to Report Q3, 2021 Results on Nov 09, 2021
2021-10-07 20:05:00
Organogenesis Holdings Inc. announced that they will report Q3, 2021 results After-Market on Nov 09, 2021
Organogenesis Holdings Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-11-2021 09:40 AM
2021-10-01 10:34:00
Organogenesis Holdings Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-11-2021 09:40 AM. Venue: Rancho Palos Verdes, California, United States. Speakers: David C. Francisco, Chief Financial Officer, Gary S. Gillheeney, President, CEO & Director.
Organogenesis Holdings Inc.(NasdaqCM:ORGO) added to S&P Global BMI Index
2021-09-20 00:00:00
Organogenesis Holdings Inc.(NasdaqCM:ORGO) added to S&P Global BMI Index
Organogenesis Holdings Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 01:15 PM
2021-09-11 05:40:00
Organogenesis Holdings Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 01:15 PM. Venue: New Windsor, United States.
Organogenesis Holdings Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-20-2021 03:45 PM
2021-09-10 13:00:00
Organogenesis Holdings Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-20-2021 03:45 PM.
Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending Ended December 31, 2021
2021-08-09 20:03:00
Organogenesis Holdings Inc. provided earnings guidance for the year ending ended December 31, 2021. For the year, the company expected net revenue of between $456 million and $472 million, representing an increase of approximately 35% to 40% year-over-year, as compared to net revenue of $338.3 million for the twelve months ended December 31, 2020. GAAP net income positive for the twelve months ended December 31, 2021.
Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021
2021-07-21 14:31:00
Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.
Organogenesis Holdings Inc. to Report Q2, 2021 Results on Aug 09, 2021
2021-07-02 11:30:00
Organogenesis Holdings Inc. announced that they will report Q2, 2021 results After-Market on Aug 09, 2021
Organogenesis Holdings Inc., Q2 2021 Earnings Call, Aug 09, 2021
2021-07-02 11:30:00
Organogenesis Holdings Inc., Q2 2021 Earnings Call, Aug 09, 2021
Fundamental Summary
Organogenesis published its Q1 report on 2022-05-10 with positive results, but no significant factors particularly remarkable relative to its peers. This typically translates into the stock performing on par with market performance for the upcoming quarter. Therefore, Organogenesis received an overall score of 64, translating into a HOLD ranking.
Organogenesis reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 98.12 million compared to USD 102.55 million a year ago. Net income was USD 0.087 million compared to USD 9.94 million a year ago.
Business Description
Organogenesis, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company’s pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Sector Overview
Organogenesis is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Organogenesis's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | 42.5 | -14.1% | 79 | |
| Net Cashflow | 30.5 | 2.8% | 76 | |
| Capital Expenditure | -32.9 | -5.5% | 63 | |
| Asset Turnover | 1.2 | -3.8% | 55 | |
| Free Cashflow | 0.2 | 3.1% | 76 |
* All values are TTM
The below chart reflects Organogenesis's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Organogenesis's peer average final assessment score stands on 72.0, Organogenesis's score is 64.
- ORGO
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Organogenesis's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Organogenesis's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 42.
5D MA
5.01
50D MA
5.87
200D MA
8.74
MACD
-0.27
RSI
12.48
STOCH
0.0
Balance Sheet Analysis
Overall, Organogenesis's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Organogenesis assets on their balance sheet, moved to 436.3, which is a -1.6% change from the last period. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its asset component earned a score of 66. Also, Organogenesis did a great job related to cash and cash equivalents this period, which stood at 107.9, representing a -5.3% change from the previous filing. This impressive growth, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its cash and cash equivalents movement earned a score of 66. That said, one metric, Equity, stood out as particularly concerning. Organogenesis management produced disappointing equity metrics this period, which stood at 243.2, representing a 0.5% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. These metrics are all the more disappointing relative to their peers and should blunt potential positive momentum in its's stock price. Consequently, their equity movement received a grade of 56. Consequently, the company's balance sheet earned a rank of 60.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 436.3 | -1.6% | 66 |
| Liabilities | 193.0 | -4.1% | 59 |
| Price to Book | 3.2 | -35.5% | 60 |
| Cash & Equivalents | 107.9 | -5.3% | 66 |
| Equity | 243.2 | 0.5% | 56 |
The below chart describes Organogenesis's performance as reflected on its balance sheet with respect to its peers. While Organogenesis received a balance sheet score of 60, the average of its peers stands on 66.0.
- ORGO
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 2 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 6 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 7 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 8 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 15 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 16 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 20 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 21 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 22 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 24 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 33 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 35 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 37 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 41 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 43 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 45 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 51 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 59 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 63 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 65 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 74 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 87 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Organogenesis appears likely to maintain its strong income statement metrics and momentum going forward. Organogenesis did an excellent job managing its revenue efficiency this past period. Organogenesis's revenue efficiency is 463.6 according to the metrics in the current filing, which represents a -0.9% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. The company's revenue efficiency, therefore, received a grade of 89. Also, In this filing, Organogenesis reported a return on equity (ROE) ratio of 42.5, which represents a change of -14.1%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 79. That said, one metric, EBITDA, stood out as strongly negative. Organogenesis's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as 89.3, which represents a -10.9% change from the last period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 55. As the companie's management is doing an excellent job managing the critical metrics, the income statement was given a score of 69.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | 89.3 | -10.9% | 55 |
| Total Revenues | 463.6 | -0.9% | 89 |
| Return on Equity | 42.5 | -14.1% | 79 |
The below chart describes Organogenesis's performance as reflected on its income statement with respect to its peers. While Organogenesis received a income statement score of 69 , the average of its peers stands on 73.0.
- ORGO
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 2 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 6 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 7 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 8 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 15 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 16 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 20 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 21 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 22 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 24 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 33 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 35 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 41 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 43 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 45 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 51 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 63 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 65 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 74 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 87 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 88 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Overall, Organogenesis's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Organogenesis's management was effective in improving their net cash flow, which now sits at 30.5 and represents a 2.8% change from the previous report. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. Hence, its net cash flow earned a score of 76. Also, Free cash flow numbers published by Organogenesis were 0.2, which was a 3.1% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. The company's free cash flow movement, therefore, received a grade of 76. On the other hand, Asset Turnover, jumped out as looking rather underwhelming. Organogenesis's asset turnover numbers were discouraging, reflecting significant concerns related to management's ability to leverage assets to generate sales effectively and efficiently. Organogenesis recorded asset turnover of 1.2, which represents a -3.8% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. The company's asset turnover metrics seem especially problematic relative to their peers. Therefore, their asset turnover movement earned a score of 55. Therefore, we scored its cash flow a 75.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | 30.5 | 2.8% | 76 |
| Capital Expenditure | -32.9 | -5.5% | 63 |
| Asset Turnover | 1.2 | -3.8% | 55 |
| Free Cashflow | 0.2 | 3.1% | 76 |
The below chart describes Organogenesis's performance as reflected on its cash flow with respect to its peers. While Organogenesis received a cash flow score of 75, the average of its peers stands on 76.0.
- ORGO
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 2 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 6 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 7 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 8 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 15 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 16 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 20 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 21 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 22 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 24 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 33 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 35 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 41 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 43 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 45 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 51 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 63 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 65 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 74 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 87 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.